Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus

Analysis of the Framingham data has shown that the risk of heart failure is increased substantially among diabetic patients, while persons with the metabolic syndrome have an increased risk of both atherosclerosis and diabetes mellitus. Sleep apnea may be related to the metabolic syndrome and systemic inflammation through hypoxia, which might also cause the cardiac remodeling by increased oxidative stress. On the other hand, the renin-angiotensin system is activated in diabetes, and local angiotensin II production may lead to oxidative damage via the angiotensin II type 1 receptor. Basic and clinical data indicate that angiotensin II receptor blockers have the potential to preserve left ventricular function and prevent cardiac remodeling that is exaggerated by oxidative stress in patients with diabetes. Thus, alleviation of oxidative stress might be one possible strategy in the treatment of diabetic patients associated with sleep apnea.

[1]  Y. Kitaura,et al.  Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. , 2008, American journal of physiology. Heart and circulatory physiology.

[2]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[3]  E. Abel,et al.  Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. , 2008, Clinical science.

[4]  D. Mann,et al.  Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[5]  Y. Kitaura,et al.  Angiotensin II Receptor Blocker Reduces Oxidative Stress and Attenuates Hypoxia-Induced Left Ventricular Remodeling in Apolipoprotein E–Knockout Mice , 2007, Hypertension Research.

[6]  A. Levy,et al.  Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  J. Sowers,et al.  Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. , 2007, American journal of physiology. Heart and circulatory physiology.

[8]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[9]  David L. Brown,et al.  Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). , 2007, The American journal of cardiology.

[10]  K. Adeli,et al.  Tumor Necrosis Factor-α Induces Intestinal Insulin Resistance and Stimulates the Overproduction of Intestinal Apolipoprotein B48-Containing Lipoproteins , 2007, Diabetes.

[11]  T. Imaizumi,et al.  Role of postprandial hyperglycaemia in cardiovascular disease in diabetes , 2007, International journal of clinical practice.

[12]  J. Manson,et al.  The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). , 2006, Circulation.

[13]  P. Rösen,et al.  Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  Krystal L. Edwards,et al.  Effect of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers on the Rate of New‐Onset Diabetes Mellitus: A Review and Pooled Analysis , 2006, Pharmacotherapy.

[15]  N. Dhalla,et al.  Oxidative stress and redox regulation of phospholipase D in myocardial disease. , 2006, Free radical biology & medicine.

[16]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[17]  M. Haidara,et al.  Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. , 2006, Current vascular pharmacology.

[18]  Y. Kitaura,et al.  Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[19]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[20]  Mark A Sussman,et al.  The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits , 2006, Circulation research.

[21]  R. Fogari,et al.  Losartan and Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients , 2006, Journal of cardiovascular pharmacology.

[22]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[23]  C. Balke,et al.  Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. , 2005, American journal of respiratory and critical care medicine.

[24]  Y. Kitaura,et al.  Chronic Hypoxia Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Knockout Mice , 2005, Hypertension Research.

[25]  E. Klann,et al.  NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. , 2005, American journal of respiratory and critical care medicine.

[26]  F. Jamali,et al.  Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions , 2005, Pharmacotherapy.

[27]  L. Wold,et al.  Oxidative stress and stress signaling: menace of diabetic cardiomyopathy , 2005, Acta Pharmacologica Sinica.

[28]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[29]  M. Rosen,et al.  Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation , 2005, Circulation.

[30]  B. Friedrich,et al.  Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. , 2005, Diabetes.

[31]  D. Gozal,et al.  Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea , 2004, Neuroscience.

[32]  M. Adachi,et al.  Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. , 2004, Chest.

[33]  David L. Williams,et al.  NF-κB activation is required for the development of cardiac hypertrophy in vivo , 2004 .

[34]  G. Nickenig.  Should Angiotensin II Receptor Blockers and Statins Be Combined? , 2004, Circulation.

[35]  J. Parish,et al.  Obstructive sleep apnea and cardiovascular disease. , 2004, Mayo Clinic proceedings.

[36]  M. Ares,et al.  Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. , 2004, International journal of cardiology.

[37]  P. Calverley,et al.  Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. , 2004, European heart journal.

[38]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[39]  A. Kashiwagi,et al.  Regulation and Role of the Mitochondrial Transcription Factor in the Diabetic Rat Heart , 2004, Annals of the New York Academy of Sciences.

[40]  N. Punjabi,et al.  Intermittent Hypoxia Increases Insulin Resistance in Genetically Obese Mice , 2003, The Journal of physiology.

[41]  Y. Kitaura,et al.  Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart , 2003, Heart.

[42]  F. Murad,et al.  Protein Tyrosine Nitration in the Mitochondria from Diabetic Mouse Heart , 2003, Journal of Biological Chemistry.

[43]  G. King,et al.  Reactive Oxygen Species and Diabetic Nephropathy , 2003 .

[44]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[45]  E. Topol,et al.  Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials , 2003, The Lancet.

[46]  H. Mori,et al.  Efficacy of Edaravone, a Free Radical Scavenger, on Left Ventricular Function and Structure in Diabetes Mellitus , 2003, Journal of cardiovascular pharmacology.

[47]  D. Gozal,et al.  Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. , 2003, American journal of respiratory and critical care medicine.

[48]  M. Adachi,et al.  Elevated Levels of C-Reactive Protein and Interleukin-6 in Patients With Obstructive Sleep Apnea Syndrome Are Decreased by Nasal Continuous Positive Airway Pressure , 2003, Circulation.

[49]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[50]  Jian-Mei Li,et al.  Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation , 2003, Circulation.

[51]  Ronald Klein,et al.  Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. , 2002, Diabetes care.

[52]  F. Coppi,et al.  Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. , 2002, Journal of the American College of Cardiology.

[53]  T. Ogihara,et al.  Nifedipine Indirectly Upregulates Superoxide Dismutase Expression in Endothelial Cells via Vascular Smooth Muscle Cell–Dependent Pathways , 2002, Circulation.

[54]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[55]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[56]  J. Hare,et al.  Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice , 2002, Circulation.

[57]  K. Lam,et al.  Obstructive sleep apnea is independently associated with insulin resistance. , 2002, American journal of respiratory and critical care medicine.

[58]  J. Sorkin,et al.  Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. , 2002, American journal of respiratory and critical care medicine.

[59]  W. Willett,et al.  What Vitamins Should I Be Taking, Doctor? , 2001 .

[60]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[61]  T. Malinski,et al.  Synergistic Antihypertensive Effects of Nifedipine on Endothelium: Concurrent Release of NO and Scavenging of Superoxide , 2001, Hypertension.

[62]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[63]  H. Utsumi,et al.  High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.

[64]  J. Engelman,et al.  Tumor Necrosis Factor α-Mediated Insulin Resistance, but Not Dedifferentiation, Is Abrogated by MEK1/2 Inhibitors in 3T3-L1 Adipocytes , 2000 .

[65]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[66]  D. Papanicolaou,et al.  Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. , 2000, The Journal of clinical endocrinology and metabolism.

[67]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[68]  G. Nickenig,et al.  Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. , 1999, Circulation.

[69]  J. Lowe,et al.  Depletion of total antioxidant capacity in type 2 diabetes. , 1999, Metabolism: Clinical and Experimental.

[70]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[71]  R. Klein,et al.  The 10-year incidence of renal insufficiency in people with type 1 diabetes. , 1999, Diabetes care.

[72]  A. Lee,et al.  Contributions of polyol pathway to oxidative stress in diabetic cataract , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  K. Kugiyama,et al.  Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. , 1998, Journal of the American College of Cardiology.

[74]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[75]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[76]  G. King,et al.  Vascular dysfunction in diabetes mellitus , 1997, The Lancet.

[77]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[78]  M. Creager,et al.  -.____----.---_-Impaired Nitric Oxide-Mediated Vasodilation in Patients With Non-Insulin-Dependent Diabetes Mellitw , 2016 .

[79]  J E Tooke,et al.  Microvascular Function in Human Diabetes: A Physiological Perspective , 1995, Diabetes.

[80]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[81]  K. Strohl,et al.  Insulin levels, blood pressure and sleep apnea. , 1994, Sleep.

[82]  P. Kaminski,et al.  NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. , 1994, The American journal of physiology.

[83]  D. Celermajer,et al.  Cigarette Smoking Is Associated With Dose‐Related and Potentially Reversible Impairment of Endothelium‐Dependent Dilation in Healthy Young Adults , 1993, Circulation.

[84]  R. Alexander,et al.  Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. , 1993, Oncogene.

[85]  R. Millman,et al.  Adiposity and cardiovascular risk factors in men with obstructive sleep apnea. , 1993, Chest.

[86]  R. Alexander,et al.  Hydrogen peroxide-induced c-fos expression is mediated by arachidonic acid release: role of protein kinase C. , 1993, Nucleic acids research.

[87]  G. Rao,et al.  Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. , 1992, Circulation research.

[88]  K. Zitnay,et al.  Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterolemia in Pig Coronary Arteries , 1988, Circulation research.

[89]  P. Bennett,et al.  Medial arterial calcification and its association with mortality and complications of diabetes , 1988, Diabetologia.

[90]  P. Dandona,et al.  Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade , 2007, Journal of Human Hypertension.

[91]  J. Schrader,et al.  Inhibition of the Renin-Angiotensin System and the Prevention of Stroke , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[92]  J. Leahy.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial , 2007 .

[93]  G. Nickenig,et al.  Interrelationship of free oxygen radicals and endothelial dysfunction--modulation by statins. , 2003, Endothelium : journal of endothelial cell research.

[94]  C W Whitney,et al.  Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. , 2001, American journal of respiratory and critical care medicine.

[95]  J. Engelman,et al.  Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. , 2000, Molecular endocrinology.

[96]  N. Hotta,et al.  Role of polyol pathway in nonenzymatic glycation. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[97]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[98]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[99]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[100]  W. Kannel,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.